RMW Cho Group

RMW Cho Group is a Hong Kong-based investment holding company and family office with a strategic focus on the life sciences and healthcare sectors. The group is the controlling shareholder of Aptorum Group, a clinical-stage biopharmaceutical company listed on the Nasdaq. RMW Cho Group facilitates the development of a broad range of therapeutic and diagnostic technologies, including treatments for orphan diseases, infectious diseases, and metabolic disorders. By providing capital and management expertise, the group aims to bridge the gap between academic research and clinical application. Their portfolio includes innovative small molecule drugs and rapid pathogen identification systems. The firm operates globally, leveraging partnerships with leading academic institutions to identify and incubate high-potential medical breakthroughs.